Mylan, Biocon release results for new trastuzumab study
Mylan N.V. and Biocon Ltd. released results of their Heritage Study in the Journal of the American Medical Association, showing positive indications for MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon. Read More »